Iloprost in Preventing Lung Cancer in Former Smokers

Lung Carcinoma Clinical Trial

Official title:

A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02237183
• Other study ID #: NCI-2014-01891
• Secondary ID: NCI-2014-01891N0
• Status: Completed
• Phase: Phase 1
• Start date: November 5, 2015
• Est. completion date: August 30, 2023

Study information

• Verified date: November 2023
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.

Description:

PRIMARY OBJECTIVES: I. To evaluate the toxicity of inhalational iloprost administered to patients daily for 2 months, given four times a day (QID). SECONDARY OBJECTIVES: I. To evaluate the compliance QID dosing regimens. II. To evaluate the effect on endobronchial histology. III. To evaluate the effect on expectorated sputum cytology by both standard cytologic analysis and an automated three-dimensional morphologic analysis. IV. To evaluate the effect on endobronchial brushing and biopsy gene expression of peroxisome proliferator-activated receptor gamma (PPARgamma), glutathione S-transferase mu (GSTmu), carboxylesterase 1 (Ces1), Fos-related antigen 1 (FosL1), cytochrome p4502e1, stearoyl coA desaturase 1, tumor necrosis factor (TNF) superfamily member 9, transforming growth factor beta (TGFbeta), Jun and a 46 gene panel associated with dysplasia persistence, using Affymetrix arrays. V. To evaluate the improvement in chronic obstructive pulmonary disease (COPD) as measured by arterial blood gas (ABG) (improved ventilation perfusion matching), pulmonary function testing, 6-minute walk distance, quality of life (St. George's respiratory questionnaire, COPD assessment test [CAT]). VI. To evaluate whether the in vitro response of cultured airway epithelial progenitor cells to iloprost is a predictor of in vivo response in study subjects. OUTLINE: Patients are enrolled to Cohort A to completion prior to initiation of Cohort B. COHORT A: Patients are assigned to 1 of 2 arms. ARM I: Patients receive iloprost via inhalation using a nebulizer QID for 60 days. ARM II: Patients receive placebo via inhalation using a nebulizer QID for 60 days. COHORT B: Patients are assigned to 1 of 2 arms. COHORT B DISCONTINUED AS OF 03/26/2019. ARM III: Patients receive iloprost via inhalation using a nebulizer BID for 60 days. ARM IV: Patients receive placebo via inhalation using a nebulizer BID for 60 days. After completion of study treatment, patients are followed up at 90 days and then annually for up to 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 30, 2023
• Est. primary completion date: March 5, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Participants must have either sputum cytologic atypia of mild dysplasia or greater or a history of bronchial biopsy with mild or greater dysplasia within the past 12 months
• Participants must have a smoking history of 20 pack-years or greater
• Participants must have the ability to safely undergo bronchoscopy in the judgment of the investigators
• Participants must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1
• Leukocytes >= 3,000/microliter
• Platelets >= 100,000/microliter
• Total bilirubin =< 2.0 mg/dl
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)
• Creatinine =< 2.0 mg/dl
• The effects of iloprost on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because prostacyclins are known to be teratogenic, women of child-bearing potential and men having intercourse with a woman of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; Note: Women are considered to be of child-bearing potential if they are not surgically sterile or are under the age of 65 and have menstruated within the last two years
• Participants must be able to understand and willing to sign a written informed consent document

Exclusion Criteria:

• Participants must not have used any tobacco product in the past year
• Participants must not be currently receiving or have previously received thiazolidinedione treatment unless sputum atypia or endobronchial dysplasia are documented again after thiazolidinedione treatment and within 12 months of entry
• Participants must not have been treated with iloprost at any time; Note: participants on the placebo arm of previous iloprost trials are eligible, but participants on the placebo arm of cohort A of this study may not be enrolled in cohort B
• Participants must not have used any other investigation agent within the last six months
• Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprost
• Participants must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that in the opinion of investigators would jeopardize patient safety of data integrity; Note: individuals who are human immunodeficiency virus (HIV) positive will not necessarily be excluded, will be considered on a case-by-case basis, but will be required to meet criteria related to patient safety and data integrity, as assessed by investigators
• Participants must not have a current or prior invasive malignancy within the past 6 months; participants may enroll prior to biopsy result report, unless there are findings at bronchoscopy suggesting an invasive malignancy; history of the following curatively treated cancers during any time prior to screening is allowed: non-melanoma skin cancer, cervical carcinoma in situ, and bladder carcinoma in situ
• Participants must not have received either chemotherapy or radiotherapy within the previous 6 months; Note: participants receiving long-term adjuvant hormonal therapy (such as tamoxifen or aromatase inhibitors for breast cancer) are allowed
• Women must not be pregnant or breastfeeding; iloprost is a prostacyclin agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with iloprost, breastfeeding should be discontinued if the mother is treated with iloprost
• As iloprost inhibits platelet function, patients must not be taking anticoagulants, with the exception of aspirin or other non-steroidal anti-inflammatory medications
• Due to risk for hypotension in patients on vasodilators or antihypertensive medications, participants must not have blood pressure < 95 mm Hg systolic

Related Conditions & MeSH terms

• Lung Carcinoma
• Lung Neoplasms

Intervention

Drug:
• Iloprost
Given via inhalation

Other:
• Placebo Administration
Given via inhalation
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
United States	UCHealth University of Colorado Hospital	Aurora	Colorado
United States	University of Colorado	Denver	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of clinical toxicity	Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Descriptive statistics (mean, standard deviation [SD], median, max, min and range) will be provided for toxicity. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.	Up to 90 days
Primary	Treatment compliance, measured as the fraction of prescribed inhalations actually administered	Descriptive statistics (mean, SD, median, max, min and range) will be provided for compliance. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.	Up to 60 days
Secondary	Response of airway histology	Will provide descriptive statistics for the effect on endobronchial histology, with the primary parameter being worst histology at matched sites; additional outcomes will be average histology, dysplasia index and response, as described.	Up to 5 years
Secondary	Serum protein profiling	Will provide descriptive statistics for the effect on serum proteins as quantitated by aptamer based analysis.	Up to 60 days
Secondary	Endobronchial brushing gene expression	Will provide descriptive statistics for the effect on endobronchial brushing gene expression, focusing on prostacyclin-targeted pathways.	Up to 60 days
Secondary	Gene expression of dysplastic lesions	Will provide descriptive statistics.	Up to 60 days
Secondary	Improvement in chronic obstructive pulmonary disease (COPD)	Will provide descriptive statistics for the improvement in COPD as measured by arterial blood gas (improved ventilation perfusion matching), pulmonary function testing, 6-minute walk distance, and quality of life (St. George's respiratory questionnaire, COPD assessment test).	Up to 60 days
Secondary	Whether the in vitro response of cultured airway epithelial progenitor cells to iloprost is a predictor of in vivo response in study subjects	Bronchial biopsies will be taken from an area suspicious for dysplasia and an area that appears normal. These will be cultured as described and transferred to an air liquid interface culture in which dysplasia is recapitulated. Cultures will be treated with either vehicle or iloprost and assessed for both self-renewal and differentiation to ciliated and secretory cells.	Up to 60 days